PCIDB

KNApSAcK Metabolite C00001179

Metabolite

KNApSAcK Entry

id C00001179
Name Vitamin C / L-Ascorbate / L-Ascorbic acid / (+)-Ascorbic acid
CAS RN 50-81-7
Standard InChI InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1
Standard InChI (Main Layer) InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2

Cluster

Phytochemical cluster
KCF-S cluster No. 8774

Link

ChEMBL

By standard InChI CHEMBL196
By standard InChI Main Layer CHEMBL196 CHEMBL1161421

KEGG

By LinkDB C00072

CTD

By CAS RN D001205

Human Protein / Gene in interaction

104 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL196 CHEMBL1909136 (2)
1 / 0
Q9H6Z9 Egl nine homolog 3 Enzyme CHEMBL196 CHEMBL1243626 (1)
0 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL196 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL196 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL196 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL196 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL196 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL196 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL196 CHEMBL1909176 (2)
0 / 0
P04746 Pancreatic alpha-amylase Hydrolase CHEMBL196 CHEMBL761495 (1)
0 / 0
P29466 Caspase-1 C14 CHEMBL196 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL196 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL196 CHEMBL1909199 (2)
0 / 0
Q9UGH3 Solute carrier family 23 member 2 Ascorbate CHEMBL196 CHEMBL802544 (1) CHEMBL802105 (1)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL196 CHEMBL1909197 (2)
2 / 2
P02545 Prelamin-A/C Unclassified protein CHEMBL196 CHEMBL1614544 (1)
11 / 10
P00918 Carbonic anhydrase 2 Lyase CHEMBL196 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL196 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL196 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL196 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL196 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL196 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909093 (2)
0 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL196 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL196 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL196 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL196 CHEMBL1909135 (2)
0 / 1
Q9GZT9 Egl nine homolog 1 Enzyme CHEMBL196 CHEMBL1243625 (1)
1 / 1
P13674 Prolyl 4-hydroxylase subunit alpha-1 Enzyme CHEMBL196 CHEMBL1243628 (1)
0 / 0
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL196 CHEMBL1909203 (2)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL196 CHEMBL1161421 CHEMBL1794311 (1) CHEMBL1794339 (1)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL196 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL196 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL196 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL196 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL196 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL196 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL196 CHEMBL1909175 (2)
0 / 0
Q96KS0 Egl nine homolog 2 Enzyme CHEMBL196 CHEMBL1243624 (1)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL196 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL196 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL196 CHEMBL1909166 (2)
1 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL196 CHEMBL1909133 (2)
0 / 0
Q9NWT6 Hypoxia-inducible factor 1-alpha inhibitor Enzyme CHEMBL196 CHEMBL1243627 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL196 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL196 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL196 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL196 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL196 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL196 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL196 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL196 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL196 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL196 CHEMBL1909167 (2)
1 / 0
P49841 Glycogen synthase kinase-3 beta Gsk CHEMBL196 CHEMBL2319565 (1)
0 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL196 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL196 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL196 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL196 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL196 CHEMBL1909119 (2)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL196 CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL196 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL196 CHEMBL1909170 (2)
0 / 0
P14679 Tyrosinase Oxidoreductase CHEMBL196 CHEMBL814348 (1)
4 / 2
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL196 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL196 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL196 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL196 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL196 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL196 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL196 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL196 CHEMBL1909108 (2)
0 / 0
P04745 Alpha-amylase 1 Enzyme CHEMBL196 CHEMBL801275 (1)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL196 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL196 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL196 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL196 CHEMBL1909132 (2)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL196 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL196 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL196 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL196 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL196 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL196 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL196 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL196 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL196 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL196 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL196 CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL196 CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL196 CHEMBL1909137 (2)
0 / 0
P27695 DNA-(apurinic or apyrimidinic site) lyase Enzyme CHEMBL1161421 CHEMBL1614211 (1)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL1161421 CHEMBL1614421 (1)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL196 CHEMBL2114890 (2)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL196 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL196 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL196 CHEMBL957655 (1) CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL196 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL196 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL196 CHEMBL1909128 (2)
0 / 0

CTD interaction (432)

compound gene gene name gene description interaction interaction type form reference
pmid
D001205 16 AARS
CMT2N
alanyl-tRNA synthetase (EC:6.1.1.7) Ascorbic Acid results in decreased expression of AARS mRNA decreases expression
mRNA 19197388
D001205 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of ABCA1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCB1 mRNA] decreases expression
/ decreases reaction
mRNA 22914566
D001205 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC1 mRNA] decreases expression
/ decreases reaction
mRNA 22914566
D001205 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Ascorbic Acid inhibits the reaction [3',4',7-trihydroxyisoflavone results in decreased expression of ABCC2 mRNA] decreases expression
/ decreases reaction
mRNA 22914566
D001205 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Ascorbic Acid inhibits the reaction [4-hydroxy-2-nonenal inhibits the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein]] decreases reaction
/ increases transport
protein 19326901
D001205 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Ascorbic Acid promotes the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein] increases reaction
/ increases transport
protein 19326901
D001205 59272 ACE2
ACEH
angiotensin I converting enzyme 2 (EC:3.4.17.23) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of ACE2 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 mRNA affects cotreatment
/ increases expression
mRNA 18607632
D001205 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 protein affects cotreatment
/ increases expression
protein 18607632
D001205 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta [Mercaptoethanol co-treated with Ascorbic Acid] results in increased expression of ACTA2 protein affects cotreatment
/ increases expression
protein 17053324
D001205 112 ADCY6
AC6
adenylate cyclase 6 (EC:4.6.1.1) Ascorbic Acid results in decreased expression of ADCY6 mRNA decreases expression
mRNA 17303424
D001205 231 AKR1B1
ADR
ALDR1
ALR2
AR
aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) Ascorbic Acid results in increased reduction of AKR1B1 protein modified form increases reduction
protein 19061876
D001205 248 ALPI
IAP
alkaline phosphatase, intestinal (EC:3.1.3.1) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of ALPI mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 290 ANPEP
APN
CD13
GP150
LAP1
P150
PEPN
alanyl (membrane) aminopeptidase (EC:3.4.11.2) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of ANPEP mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 301 ANXA1
ANX1
LPC1
annexin A1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of ANXA1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 335 APOA1
apolipoprotein A-I Ascorbic Acid results in decreased expression of APOA1 mRNA decreases expression
mRNA 16423621
D001205 335 APOA1
apolipoprotein A-I Ascorbic Acid results in decreased expression of APOA1 protein decreases expression
protein 16423621
D001205 338 APOB
FLDB
LDLCQ4
apolipoprotein B Ascorbic Acid promotes the reaction [Flavonoids inhibits the reaction [Copper results in increased oxidation of APOB protein]] decreases reaction
/ increases oxidation
/ increases reaction
protein 17475462
D001205 338 APOB
FLDB
LDLCQ4
apolipoprotein B Ascorbic Acid promotes the reaction [Quercetin inhibits the reaction [Copper results in increased oxidation of APOB protein]] decreases reaction
/ increases oxidation
/ increases reaction
protein 17475462
D001205 338 APOB
FLDB
LDLCQ4
apolipoprotein B [Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOB mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 55937 APOM
G3a
HSPC336
NG20
apo-M
apolipoprotein M [Quercetin co-treated with Ascorbic Acid] results in decreased expression of APOM mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide affects binding
/ affects cotreatment
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein [[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal affects binding
/ affects cotreatment
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines affects binding
/ affects cotreatment
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein [[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide affects binding
/ affects cotreatment
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein APP protein modified form inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] affects cotreatment
/ decreases reaction
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein [APP protein modified form inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide]] which results in increased chemical synthesis of 4-hydroxy-2-nonenal affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein APP protein modified form results in increased oxidation of Ascorbic Acid increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Copper promotes the reaction [APP protein modified form results in increased oxidation of Ascorbic Acid] increases oxidation
/ increases reaction
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 351 APP
AAA
ABETA
ABPP
AD1
APPI
CTFgamma
CVAP
PN-II
PN2
amyloid beta (A4) precursor protein Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
/ increases oxidation
protein 17964426
D001205 360 AQP3
AQP-3
GIL
aquaporin 3 (Gill blood group) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of AQP3 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 397 ARHGDIB
D4
GDIA2
GDID4
LYGDI
Ly-GDI
RAP1GN1
RhoGDI2
Rho GDP dissociation inhibitor (GDI) beta [Quercetin co-treated with Ascorbic Acid] results in increased expression of ARHGDIB mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 440 ASNS
TS11
asparagine synthetase (glutamine-hydrolyzing) (EC:6.3.5.4) Ascorbic Acid results in decreased expression of ASNS mRNA decreases expression
mRNA 19197388
D001205 467 ATF3
activating transcription factor 3 [Quercetin co-treated with Ascorbic Acid] results in increased expression of ATF3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 9212 AURKB
AIK2
AIM-1
AIM1
ARK2
AurB
IPL1
PPP1R48
STK12
STK5
aurkb-sv1
aurkb-sv2
aurora kinase B (EC:2.7.11.1) [Quercetin co-treated with Ascorbic Acid] results in increased expression of AURKB mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 581 BAX
BCL2L4
BCL2-associated X protein Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of BAX protein] decreases reaction
/ increases expression
protein 17166419
D001205 581 BAX
BCL2L4
BCL2-associated X protein Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of BAX mRNA] decreases reaction
/ increases expression
mRNA 22245848
D001205 581 BAX
BCL2L4
BCL2-associated X protein Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of BAX protein] decreases reaction
/ increases expression
protein 22245848
D001205 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein affects cotreatment
/ decreases expression
protein 20530418
D001205 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 20530418
D001205 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Ascorbic Acid inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 17166419
D001205 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 mRNA] decreases expression
/ decreases reaction
mRNA 22245848
D001205 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 22245848
D001205 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Ascorbic Acid results in decreased expression of BCL2 mRNA decreases expression
mRNA 21919647
D001205 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 protein results in increased abundance of Ascorbic Acid increases abundance
protein 15449323
D001205 79370 BCL2L14
BCLG
BCL2-like 14 (apoptosis facilitator) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of BCL2L14 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 632 BGLAP
BGP
OC
OCN
bone gamma-carboxyglutamate (gla) protein [Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BGLAP mRNA affects cotreatment
/ increases expression
mRNA 12510807
D001205 632 BGLAP
BGP
OC
OCN
bone gamma-carboxyglutamate (gla) protein [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein affects cotreatment
/ increases expression
protein 17692823
D001205 12095 [Ascorbic Acid co-treated with Copper] affects the cleavage of BGLAP3 protein affects cleavage
/ affects cotreatment
protein 11396734
D001205 12095 BGLAP3 protein binds to Ascorbic Acid affects binding
protein 11396734
D001205 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 [Quercetin co-treated with Ascorbic Acid] results in increased expression of BIRC3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Ascorbic Acid results in decreased expression of BIRC5 mRNA decreases expression
mRNA 21919647
D001205 699 BUB1
BUB1A
BUB1L
hBUB1
BUB1 mitotic checkpoint serine/threonine kinase (EC:2.7.11.1) [Quercetin co-treated with Ascorbic Acid] results in increased expression of BUB1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 768 CA9
CAIX
MN
carbonic anhydrase IX (EC:4.2.1.1) Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of CA9 protein] decreases reaction
/ increases expression
protein 16288478
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein] decreases reaction
/ increases expression
protein 17166419
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid inhibits the reaction [Fenretinide results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 16124896
16407847
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid inhibits the reaction [Reactive Oxygen Species results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 16124896
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of CASP3 mRNA] decreases expression
/ decreases reaction
mRNA 22245848
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 22245848
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 12750841
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid promotes the reaction [arsenic trioxide results in increased cleavage of and results in increased activity of CASP3 protein] increases activity
/ increases cleavage
/ increases reaction
protein 16867262
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid promotes the reaction [chromium hexavalent ion results in increased cleavage of CASP3 protein] increases cleavage
/ increases reaction
protein 17301063
D001205 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Ascorbic Acid results in decreased activity of CASP3 protein decreases activity
protein 17618090
D001205 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Ascorbic Acid promotes the reaction [chromium hexavalent ion results in increased cleavage of CASP7 protein] increases cleavage
/ increases reaction
protein 17301063
D001205 847 CAT
catalase (EC:1.11.1.6) Ascorbic Acid affects the expression of CAT protein affects expression
protein 10772068
D001205 847 CAT
catalase (EC:1.11.1.6) [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Air Pollutants, Occupational affects the expression of CAT protein] affects cotreatment
/ affects expression
/ decreases reaction
protein 20535553
D001205 847 CAT
catalase (EC:1.11.1.6) [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [Malathion results in increased activity of CAT protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 18655177
D001205 847 CAT
catalase (EC:1.11.1.6) [Ascorbic Acid co-treated with Vitamin E] results in increased expression of CAT mRNA affects cotreatment
/ increases expression
mRNA 22207723
D001205 847 CAT
catalase (EC:1.11.1.6) Ascorbic Acid inhibits the reaction [Dimethoate results in increased activity of CAT protein] decreases reaction
/ increases activity
protein 20077558
D001205 847 CAT
catalase (EC:1.11.1.6) Ascorbic Acid inhibits the reaction [Malathion results in increased activity of CAT protein] decreases reaction
/ increases activity
protein 18655177
D001205 847 CAT
catalase (EC:1.11.1.6) CAT protein inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 847 CAT
catalase (EC:1.11.1.6) CAT protein results in decreased susceptibility to [arsenic trioxide co-treated with Ascorbic Acid] affects cotreatment
/ decreases response to substance
protein 20171736
D001205 847 CAT
catalase (EC:1.11.1.6) CAT protein results in decreased susceptibility to Ascorbic Acid decreases response to substance
protein 14698046
D001205 847 CAT
catalase (EC:1.11.1.6) CAT results in decreased susceptibility to [Vitamin K 3 co-treated with Ascorbic Acid] affects cotreatment
/ decreases response to substance
21689642
D001205 875 CBS
HIP4
cystathionine-beta-synthase (EC:4.2.1.22) Ascorbic Acid results in decreased expression of CBS mRNA decreases expression
mRNA 19197388
D001205 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Ascorbic Acid affects the expression of CCL2 mRNA affects expression
mRNA 19932582
D001205 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 Ascorbic Acid deficiency affects the expression of CCL2 mRNA affects expression
mRNA 19932582
D001205 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Ascorbic Acid results in decreased expression of CCND1 mRNA decreases expression
mRNA 21919647
D001205 894 CCND2
KIAK0002
cyclin D2 [Quercetin co-treated with Ascorbic Acid] results in increased expression of CCND2 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 100133941 CD24
CD24A
CD24 molecule [Quercetin co-treated with Ascorbic Acid] results in increased expression of CD24 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 947 CD34
CD34 molecule [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CD34 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 958 CD40
Bp50
CDW40
TNFRSF5
p50
CD40 molecule, TNF receptor superfamily member 5 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CD40 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 990 CDC6
CDC18L
HsCDC18
HsCDC6
cell division cycle 6 [Quercetin co-treated with Ascorbic Acid] results in increased expression of CDC6 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 728642 CDK11A
CDC2L2
CDC2L3
CDK11-p110
CDK11-p46
CDK11-p58
PITSLRE
p58GTA
cyclin-dependent kinase 11A (EC:2.7.11.22) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of CDK11A mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA affects cotreatment
/ decreases expression
mRNA 20530418
D001205 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Ascorbic Acid inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 20067818
D001205 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 20530418
D001205 629 CFB
AHUS4
BF
BFD
CFAB
FB
FBI12
GBG
H2-Bf
PBF2
complement factor B (EC:3.4.21.47) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of CFB mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 1080 CFTR
ABC35
ABCC7
CF
CFTR/MRP
MRP7
TNR-CFTR
dJ760C5.1
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) Ascorbic Acid promotes the reaction [CFTR protein results in increased secretion of Chlorides] increases reaction
/ increases secretion
protein 14993613
D001205 1080 CFTR
ABC35
ABCC7
CF
CFTR/MRP
MRP7
TNR-CFTR
dJ760C5.1
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) Ascorbic Acid results in increased activity of CFTR protein increases activity
protein 14993613
D001205 11113 CIT
CRIK
STK21
citron (rho-interacting, serine/threonine kinase 21) (EC:2.7.11.1) [Quercetin co-treated with Ascorbic Acid] results in increased expression of CIT mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 1264 CNN1
SMCC
Sm-Calp
calponin 1, basic, smooth muscle [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 mRNA affects cotreatment
/ increases expression
mRNA 18607632
D001205 1264 CNN1
SMCC
Sm-Calp
calponin 1, basic, smooth muscle [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 protein affects cotreatment
/ increases expression
protein 18607632
D001205 1270 CNTF
HCNTF
ciliary neurotrophic factor Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT1 protein]] decreases reaction
/ increases phosphorylation
protein 16896058
D001205 1270 CNTF
HCNTF
ciliary neurotrophic factor Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]] decreases reaction
/ increases phosphorylation
protein 16896058
D001205 1277 COL1A1
OI4
collagen, type I, alpha 1 Ascorbic Acid results in increased expression of COL1A1 mRNA increases expression
mRNA 12510807
D001205 1380 CR2
C3DR
CD21
CR
CVID7
SLEB9
complement component (3d/Epstein Barr virus) receptor 2 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CR2 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 1401 CRP
PTX1
C-reactive protein, pentraxin-related [Vitamin E co-treated with Ascorbic Acid co-treated with Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein affects cotreatment
/ decreases expression
protein 16517955
D001205 1401 CRP
PTX1
C-reactive protein, pentraxin-related [Vitamin E co-treated with Ascorbic Acid] results in decreased expression of CRP protein affects cotreatment
/ decreases expression
protein 16517955
D001205 1519 CTSO
CTSO1
cathepsin O (EC:3.4.22.42) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of CTSO mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 3627 CXCL10
C7
IFI10
INP10
IP-10
SCYB10
crg-2
gIP-10
mob-1
chemokine (C-X-C motif) ligand 10 Ascorbic Acid deficiency results in increased expression of CXCL10 mRNA increases expression
mRNA 19932582
D001205 3627 CXCL10
C7
IFI10
INP10
IP-10
SCYB10
crg-2
gIP-10
mob-1
chemokine (C-X-C motif) ligand 10 Ascorbic Acid results in decreased expression of CXCL10 mRNA decreases expression
mRNA 19932582
D001205 6372 CXCL6
CKA-3
GCP-2
GCP2
SCYB6
chemokine (C-X-C motif) ligand 6 Ascorbic Acid deficiency results in increased expression of CXCL6 mRNA increases expression
mRNA 19932582
D001205 6372 CXCL6
CKA-3
GCP-2
GCP2
SCYB6
chemokine (C-X-C motif) ligand 6 Ascorbic Acid results in decreased expression of CXCL6 mRNA decreases expression
mRNA 19932582
D001205 4283 CXCL9
CMK
Humig
MIG
SCYB9
crg-10
chemokine (C-X-C motif) ligand 9 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of CXCL9 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 643 CXCR5
BLR1
CD185
MDR15
chemokine (C-X-C motif) receptor 5 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of CXCR5 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 79901 CYBRD1
CYB561A2
DCYTB
FRRS3
cytochrome b reductase 1 Ascorbic Acid results in decreased expression of CYBRD1 protein decreases expression
protein 18815723
D001205 79901 CYBRD1
CYB561A2
DCYTB
FRRS3
cytochrome b reductase 1 Ascorbic Acid results in increased expression of CYBRD1 protein increases expression
protein 18815723
D001205 1583 CYP11A1
CYP11A
CYPXIA1
P450SCC
cytochrome P450, family 11, subfamily A, polypeptide 1 (EC:1.14.15.6) Ascorbic Acid results in increased expression of CYP11A1 mRNA increases expression
mRNA 17901237
D001205 1588 CYP19A1
ARO
ARO1
CPV1
CYAR
CYP19
CYPXIX
P-450AROM
cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) Ascorbic Acid results in increased expression of CYP19A1 mRNA increases expression
mRNA 17901237
D001205 1588 CYP19A1
ARO
ARO1
CPV1
CYAR
CYP19
CYPXIX
P-450AROM
cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of CYP19A1 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] decreases reaction
/ increases activity
protein 19268519
D001205 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] decreases reaction
/ increases expression
mRNA 19268519
D001205 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Ascorbic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] decreases reaction
/ increases expression
protein 19268519
D001205 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) Ascorbic Acid results in decreased activity of CYP1A1 protein decreases activity
protein 17512695
D001205 1543 CYP1A1
AHH
AHRR
CP11
CYP1
P1-450
P450-C
P450DX
cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) [Quercetin co-treated with Ascorbic Acid] results in increased expression of CYP1A1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 1548 CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) Ascorbic Acid results in decreased activity of CYP2A6 protein decreases activity
protein 17512695
D001205 1556 CYP2B7P
CYP2B
CYP2B7
CYP2B7P1
cytochrome P450, family 2, subfamily B, polypeptide 7, pseudogene [Quercetin co-treated with Ascorbic Acid] results in decreased expression of CYP2B7P1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) Ascorbic Acid results in decreased activity of CYP2E1 protein decreases activity
protein 17512695
D001205 22943 DKK1
DKK-1
SK
dickkopf WNT signaling pathway inhibitor 1 Ascorbic Acid results in decreased expression of DKK1 mRNA decreases expression
mRNA 19197388
D001205 9787 DLGAP5
DLG7
HURP
discs, large (Drosophila) homolog-associated protein 5 [Quercetin co-treated with Ascorbic Acid] results in increased expression of DLGAP5 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 54431 DNAJC10
ERdj5
JPDI
MTHr
PDIA19
DnaJ (Hsp40) homolog, subfamily C, member 10 Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of DNAJC10 mRNA] decreases reaction
/ increases expression
mRNA 17353921
D001205 1773 DNASE1
DNL1
DRNI
deoxyribonuclease I (EC:3.1.21.1) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of DNASE1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 1803 DPP4
ADABP
ADCP2
CD26
DPPIV
TP103
dipeptidyl-peptidase 4 (EC:3.4.14.5) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of DPP4 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 1906 EDN1
ET1
HDLCQ7
PPET1
endothelin 1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of EDN1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 1908 EDN3
ET-3
ET3
HSCR4
PPET3
WS4B
endothelin 3 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of EDN3 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Ascorbic Acid results in decreased expression of EGFR mRNA decreases expression
mRNA 21919647
D001205 112399 EGLN3
HIFP4H3
HIFPH3
PHD3
egl-9 family hypoxia-inducible factor 3 (EC:1.14.11.29) [Quercetin co-treated with Ascorbic Acid] results in increased expression of EGLN3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 8894 EIF2S2
EIF2
EIF2B
EIF2beta
PPP1R67
eIF-2-beta
eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa Ascorbic Acid results in decreased expression of EIF2S2 mRNA decreases expression
mRNA 19197388
D001205 8661 EIF3A
EIF3
EIF3S10
P167
TIF32
eIF3-p170
eIF3-theta
p180
p185
eukaryotic translation initiation factor 3, subunit A Ascorbic Acid results in decreased expression of EIF3A mRNA decreases expression
mRNA 19197388
D001205 8343525 Ascorbic Acid results in decreased expression of EIF3S8 mRNA decreases expression
mRNA 19197388
D001205 1973 EIF4A1
DDX2A
EIF-4A
EIF4A
eIF-4A-I
eIF4A-I
eukaryotic translation initiation factor 4A1 (EC:3.6.4.13) Ascorbic Acid results in decreased expression of EIF4A1 mRNA decreases expression
mRNA 19197388
D001205 2012 EMP1
CL-20
EMP-1
TMP
epithelial membrane protein 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of EMP1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 2014 EMP3
YMP
epithelial membrane protein 3 [Quercetin co-treated with Ascorbic Acid] results in increased expression of EMP3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 2034 EPAS1
ECYT4
HIF2A
HLF
MOP2
PASD2
bHLHe73
endothelial PAS domain protein 1 Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of EPAS1 protein] decreases reaction
/ increases expression
protein 16288478
D001205 2052 EPHX1
EPHX
EPOX
HYL1
MEH
epoxide hydrolase 1, microsomal (xenobiotic) (EC:3.3.2.9) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of EPHX1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2053 EPHX2
CEH
SEH
epoxide hydrolase 2, cytoplasmic (EC:3.3.2.10 3.1.3.76) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of EPHX2 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2058 EPRS
EARS
GLUPRORS
PARS
QARS
QPRS
glutamyl-prolyl-tRNA synthetase (EC:6.1.1.15 6.1.1.17) Ascorbic Acid results in decreased expression of EPRS mRNA decreases expression
mRNA 19197388
D001205 2172 FABP6
I-15P
I-BABP
I-BALB
I-BAP
ILBP
ILBP3
ILLBP
fatty acid binding protein 6, ileal [Quercetin co-treated with Ascorbic Acid] results in decreased expression of FABP6 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2321 FLT1
FLT
FLT-1
VEGFR-1
VEGFR1
fms-related tyrosine kinase 1 (EC:2.7.10.1) Ascorbic Acid results in decreased expression of FLT1 mRNA decreases expression
mRNA 21919647
D001205 2326 FMO1
flavin containing monooxygenase 1 (EC:1.14.13.8) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of FMO1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2330 FMO5
flavin containing monooxygenase 5 (EC:1.14.13.8) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of FMO5 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2335 FN1
CIG
ED-B
FINC
FN
FNZ
GFND
GFND2
LETS
MSF
fibronectin 1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of FN1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 2302 FOXJ1
FKHL13
HFH-4
HFH4
forkhead box J1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of FOXJ1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 2534 FYN
SLK
SYN
p59-FYN
FYN oncogene related to SRC, FGR, YES (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of FYN protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 2534 FYN
SLK
SYN
p59-FYN
FYN oncogene related to SRC, FGR, YES (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of FYN protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 2535 FZD2
Fz2
fz-2
fzE2
hFz2
frizzled family receptor 2 [Quercetin co-treated with Ascorbic Acid] results in increased expression of FZD2 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 50486 G0S2
RP1-28O10.2
G0/G1switch 2 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of G0S2 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2580 GAK
DNAJ26
DNAJC26
cyclin G associated kinase (EC:2.7.11.1) [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of GAK mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 2617 GARS
CMT2D
DSMAV
GlyRS
HMN5
SMAD1
glycyl-tRNA synthetase (EC:6.1.1.14) Ascorbic Acid results in decreased expression of GARS mRNA decreases expression
mRNA 19197388
D001205 2623 GATA1
ERYF1
GATA-1
GF-1
GF1
NF-E1
NFE1
XLANP
XLTDA
XLTT
GATA binding protein 1 (globin transcription factor 1) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of GATA1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 2674 GFRA1
GDNFR
GDNFRA
GFR-ALPHA-1
RET1L
RETL1
TRNR1
GDNF family receptor alpha 1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of GFRA1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 2744 GLS
AAD20
GAC
GAM
GLS1
KGA
glutaminase (EC:3.5.1.2) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of GLS mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) [Ascorbic Acid co-treated with Vitamin E] results in increased expression of GPX1 mRNA affects cotreatment
/ increases expression
mRNA 22207723
D001205 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA affects cotreatment
/ decreases expression
mRNA 20530418
D001205 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 20530418
D001205 2876 GPX1
GPXD
GSHPX1
glutathione peroxidase 1 (EC:1.11.1.9) [Vitamin A co-treated with Ascorbic Acid co-treated with Vitamin E] results in increased expression of GPX1 protein affects cotreatment
/ increases expression
protein 17179735
D001205 2877 GPX2
GI-GPx
GPRP
GPRP-2
GPx-2
GPx-GI
GSHPX-GI
GSHPx-2
glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) [Quercetin co-treated with Ascorbic Acid] results in increased expression of GPX2 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 2877 GPX2
GI-GPx
GPRP
GPRP-2
GPx-2
GPx-GI
GSHPX-GI
GSHPx-2
glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of GPX2 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 2936 GSR
glutathione reductase (EC:1.8.1.7) [Ascorbic Acid co-treated with GSR protein] affects the metabolism of Glucose affects cotreatment
/ affects metabolic processing
protein 1901343
D001205 2938 GSTA1
GST2
GSTA1-1
GTH1
glutathione S-transferase alpha 1 (EC:2.5.1.18) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of GSTA1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 affects the susceptibility to Ascorbic Acid deficiency affects response to substance
19710200
D001205 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 gene polymorphism affects the susceptibility to [Ascorbic Acid co-treated with tocotrienol, alpha] affects cotreatment
/ affects response to substance
gene 15668500
D001205 2952 GSTT1
glutathione S-transferase theta 1 (EC:2.5.1.18) GSTT1 affects the susceptibility to Ascorbic Acid deficiency affects response to substance
19710200
D001205 2965 GTF2H1
BTF2
P62
TFB1
TFIIH
general transcription factor IIH, polypeptide 1, 62kDa [Quercetin co-treated with Ascorbic Acid] results in decreased expression of GTF2H1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X [Ascorbic Acid results in increased reduction of Vitamin K 3] which results in increased phosphorylation of H2AFX protein increases phosphorylation
/ increases reduction
protein 19482829
D001205 9843 HEPH
CPL
hephaestin [Quercetin co-treated with Ascorbic Acid] results in decreased expression of HEPH mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 9709 HERPUD1
HERP
Mif1
SUP
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 Ascorbic Acid results in decreased expression of HERPUD1 mRNA decreases expression
mRNA 19197388
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [chromium hexavalent ion results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 17382205
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [cupric chloride results in decreased hydroxylation of HIF1A protein] decreases hydroxylation
/ decreases reaction
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [cupric chloride results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [manganese chloride results in decreased hydroxylation of HIF1A protein] decreases hydroxylation
/ decreases reaction
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [manganese chloride results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [nickel sulfate results in decreased hydroxylation of HIF1A protein] decreases hydroxylation
/ decreases reaction
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 16288478
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [nickel sulfate results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 17382205
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [potassium chromate(VI) results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 17382205
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [Quercetin results in increased expression of HIF1A protein] decreases reaction
/ increases expression
protein 17364964
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [sodium arsenite results in decreased hydroxylation of HIF1A protein] decreases hydroxylation
/ decreases reaction
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [Vanadates results in decreased hydroxylation of HIF1A protein] decreases hydroxylation
/ decreases reaction
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid inhibits the reaction [Vanadates results in increased stability of HIF1A protein] decreases reaction
/ increases stability
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) Ascorbic Acid results in increased degradation of HIF1A protein increases degradation
protein 19074761
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with alpha-ketoglutaric acid co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein] affects binding
/ affects cotreatment
/ increases reaction
protein 19263519
D001205 3091 HIF1A
HIF-1A
HIF-1alpha
HIF1
HIF1-ALPHA
MOP1
PASD8
bHLHe78
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with alpha-ketoglutaric acid co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]] affects binding
/ affects cotreatment
/ decreases reaction
/ increases reaction
protein 19263519
D001205 3098 HK1
HK1-ta
HK1-tb
HK1-tc
HKD
HKI
HMSNR
HXK1
hexokinase 1 (EC:2.7.1.1) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of HK1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Ascorbic Acid inhibits the reaction [benzo(a)pyrene-7,8-dione results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 22053912
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Ascorbic Acid inhibits the reaction [HMOX1 protein results in increased expression of SOD2 mRNA] decreases reaction
/ increases expression
protein 10942521
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Ascorbic Acid inhibits the reaction [resveratrol results in increased expression of HMOX1 mRNA] decreases reaction
/ increases expression
mRNA 21199573
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Ascorbic Acid inhibits the reaction [resveratrol results in increased expression of HMOX1 protein] decreases reaction
/ increases expression
protein 21199573
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Ascorbic Acid results in increased expression of HMOX1 mRNA increases expression
mRNA 8743975
D001205 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19683516
D001205 3240 HP
BP
HP2ALPHA2
HPA1S
haptoglobin Ascorbic Acid affects the activity of HP protein polymorphism affects activity
protein 19769483
D001205 3240 HP
BP
HP2ALPHA2
HPA1S
haptoglobin HP gene polymorphism affects the susceptibility to Ascorbic Acid deficiency affects response to substance
gene 20926521
D001205 3283 HSD3B1
3BETAHSD
HSD3B
HSDB3
HSDB3A
I
SDR11E1
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (EC:1.1.1.145 5.3.3.1) Ascorbic Acid results in increased expression of HSD3B1 mRNA increases expression
mRNA 17901237
D001205 3303 HSPA1A
HSP70-1
HSP70-1A
HSP70I
HSP72
HSPA1
heat shock 70kDa protein 1A [Quercetin co-treated with Ascorbic Acid] results in increased expression of HSPA1A mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 3309 HSPA5
BIP
GRP78
MIF2
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of HSPA5 protein] decreases reaction
/ increases expression
protein 17353921
D001205 3309 HSPA5
BIP
GRP78
MIF2
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Ascorbic Acid results in decreased expression of HSPA5 mRNA decreases expression
mRNA 19197388
D001205 3313 HSPA9
CSA
GRP-75
GRP75
HSPA9B
MOT
MOT2
MTHSP75
PBP74
heat shock 70kDa protein 9 (mortalin) Ascorbic Acid results in decreased expression of HSPA9 mRNA decreases expression
mRNA 19197388
D001205 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of HSPB1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 3347 HTN3
HIS2
HTN2
HTN5
histatin 3 [HTN3 protein modified form co-treated with Copper co-treated with Ascorbic Acid] results in increased abundance of Hydrogen Peroxide affects cotreatment
/ increases abundance
protein 18975018
D001205 3376 IARS
IARS1
ILERS
ILRS
IRS
PRO0785
isoleucyl-tRNA synthetase (EC:6.1.1.5) Ascorbic Acid results in decreased expression of IARS mRNA decreases expression
mRNA 19197388
D001205 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Ascorbic Acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 12723939
D001205 8870 IER3
DIF-2
DIF2
GLY96
IEX-1
IEX-1L
IEX1
PRG1
immediate early response 3 [Quercetin co-treated with Ascorbic Acid] results in increased expression of IER3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 3488 IGFBP5
IBP5
insulin-like growth factor binding protein 5 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 10320 IKZF1
Hs.54452
IK1
IKAROS
LYF1
PRO0758
ZNFN1A1
hIk-1
IKAROS family zinc finger 1 (Ikaros) 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [Ascorbic Acid results in decreased activity of IKZF1 protein] decreases activity
/ decreases reaction
protein 17664058
D001205 10320 IKZF1
Hs.54452
IK1
IKAROS
LYF1
PRO0758
ZNFN1A1
hIk-1
IKAROS family zinc finger 1 (Ikaros) 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate inhibits the reaction [Ascorbic Acid results in decreased activity of IKZF1 protein] decreases activity
/ decreases reaction
protein 17664058
D001205 10320 IKZF1
Hs.54452
IK1
IKAROS
LYF1
PRO0758
ZNFN1A1
hIk-1
IKAROS family zinc finger 1 (Ikaros) Ascorbic Acid results in decreased activity of IKZF1 protein decreases activity
protein 17664058
D001205 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha] decreases reaction
/ increases chemical synthesis
16529823
D001205 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone] decreases reaction
/ increases chemical synthesis
16529823
D001205 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]] decreases reaction
/ increases chemical synthesis
/ increases reaction
16529823
D001205 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]] decreases reaction
/ increases chemical synthesis
/ increases reaction
16529823
D001205 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ascorbic Acid affects the expression of IL8 mRNA affects expression
mRNA 19932582
D001205 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ascorbic Acid affects the reaction [Homocysteine results in increased secretion of IL8 protein] affects reaction
/ increases secretion
protein 16715183
D001205 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ascorbic Acid affects the reaction [homocysteine thiolactone results in increased secretion of IL8 protein] affects reaction
/ increases secretion
protein 16715183
D001205 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ascorbic Acid deficiency affects the expression of IL8 mRNA affects expression
mRNA 19932582
D001205 3745 KCNB1
DRK1
KV2.1
h-DRK1
potassium voltage-gated channel, Shab-related subfamily, member 1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of KCNB1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 3791 KDR
CD309
FLK1
VEGFR
VEGFR2
kinase insert domain receptor (a type III receptor tyrosine kinase) (EC:2.7.10.1) Ascorbic Acid results in decreased expression of KDR mRNA decreases expression
mRNA 21919647
D001205 9493 KIF23
CHO1
KNSL5
MKLP-1
MKLP1
kinesin family member 23 [Quercetin co-treated with Ascorbic Acid] results in increased expression of KIF23 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 3932 LCK
LSK
YT16
p56lck
pp58lck
lymphocyte-specific protein tyrosine kinase (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 3932 LCK
LSK
YT16
p56lck
pp58lck
lymphocyte-specific protein tyrosine kinase (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 3956 LGALS1
GAL1
GBP
lectin, galactoside-binding, soluble, 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of LGALS1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 4017 LOXL2
LOR2
WS9-14
lysyl oxidase-like 2 (EC:1.4.3.-) Ascorbic Acid results in decreased expression of LOXL2 mRNA decreases expression
mRNA 19197388
D001205 4067 LYN
JTK8
p53Lyn
p56Lyn
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LYN protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 4067 LYN
JTK8
p53Lyn
p56Lyn
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (EC:2.7.10.2) Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LYN protein] decreases reaction
/ increases phosphorylation
protein 14572611
D001205 23764 MAFF
U-MAF
hMafF
v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F [Quercetin co-treated with Ascorbic Acid] results in increased expression of MAFF mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 10892 MALT1
IMD12
MLT
MLT1
mucosa associated lymphoid tissue lymphoma translocation gene 1 (EC:3.4.22.-) [Quercetin co-treated with Ascorbic Acid] results in increased expression of MALT1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 5606 MAP2K3
MAPKK3
MEK3
MKK3
PRKMK3
SAPKK-2
SAPKK2
mitogen-activated protein kinase kinase 3 (EC:2.7.12.2) Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K3 protein] decreases reaction
/ increases phosphorylation
protein 16407847
D001205 5608 MAP2K6
MAPKK6
MEK6
MKK6
PRKMK6
SAPKK-3
SAPKK3
mitogen-activated protein kinase kinase 6 (EC:2.7.12.2) Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K6 protein] decreases reaction
/ increases phosphorylation
protein 16407847
D001205 4217 MAP3K5
ASK1
MAPKKK5
MEKK5
mitogen-activated protein kinase kinase kinase 5 (EC:2.7.11.25) Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAP3K5 protein] decreases reaction
/ increases phosphorylation
protein 20206247
D001205 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAPK14 protein] decreases reaction
/ increases phosphorylation
protein 16407847
D001205 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein] decreases reaction
/ increases phosphorylation
protein 20206247
D001205 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) Ascorbic Acid inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein] decreases reaction
/ increases phosphorylation
protein 20206247
D001205 4173 MCM4
CDC21
CDC54
NKCD
NKGCD
P1-CDC21
hCdc21
minichromosome maintenance complex component 4 (EC:3.6.4.12) [Quercetin co-treated with Ascorbic Acid] results in increased expression of MCM4 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 4224 MEP1A
PPHA
meprin A, alpha (PABA peptide hydrolase) (EC:3.4.24.18) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of MEP1A mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 4233 MET
AUTS9
HGFR
RCCP2
c-Met
met proto-oncogene (EC:2.7.10.1) Ascorbic Acid results in decreased expression of MET mRNA decreases expression
mRNA 21919647
D001205 4288 MKI67
KIA
MIB-1
marker of proliferation Ki-67 [Quercetin co-treated with Ascorbic Acid] results in increased expression of MKI67 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 Ascorbic Acid promotes the reaction [MLH1 gene mutant form results in decreased susceptibility to chromium hexavalent ion] decreases response to substance
/ increases reaction
gene 15831465
D001205 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 MLH1 protein promotes the reaction [Ascorbic Acid results in increased susceptibility to chromium hexavalent ion] increases reaction
/ increases response to substance
protein 17301063
D001205 4292 MLH1
COCA2
FCC2
HNPCC
HNPCC2
hMLH1
mutL homolog 1 MLH1 protein results in increased susceptibility to [chromium hexavalent ion co-treated with Ascorbic Acid] affects cotreatment
/ increases response to substance
protein 17169990
D001205 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) Ascorbic Acid inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MMP1 mRNA] decreases reaction
/ increases expression
mRNA 10836612
D001205 4316 MMP7
MMP-7
MPSL1
PUMP-1
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) [Quercetin co-treated with Ascorbic Acid] results in increased expression of MMP7 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 4353 MPO
myeloperoxidase (EC:1.11.2.2) Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol] affects cotreatment
/ decreases reaction
/ increases oxidation
protein 19462961
D001205 4353 MPO
myeloperoxidase (EC:1.11.2.2) Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Fenoterol] affects cotreatment
/ decreases reaction
/ increases oxidation
protein 19462961
D001205 4436 MSH2
COCA1
FCC1
HNPCC
HNPCC1
LCFS2
mutS homolog 2 MSH2 protein promotes the reaction [Ascorbic Acid results in increased susceptibility to chromium hexavalent ion] increases reaction
/ increases response to substance
protein 17301063
D001205 4436 MSH2
COCA1
FCC1
HNPCC
HNPCC1
LCFS2
mutS homolog 2 MSH2 protein results in increased susceptibility to [chromium hexavalent ion co-treated with Ascorbic Acid] affects cotreatment
/ increases response to substance
protein 17169990
D001205 4485 MST1
D3F15S2
DNF15S2
HGFL
MSP
NF15S2
macrophage stimulating 1 (hepatocyte growth factor-like) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of MST1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 11223 MST1L
BRF-1
D1F15S1A
MSPL-7
MSPL7
MST1P9
MSTP7
MSTP9
macrophage stimulating 1-like [Quercetin co-treated with Ascorbic Acid] results in decreased expression of MST1L mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 4504 MT3
GIF
GIFB
GRIF
ZnMT3
metallothionein 3 [[MT3 protein binds to Zinc] which co-treated with Ascorbic Acid] inhibits the reaction [Copper results in increased chemical synthesis of Hydroxyl Radical] affects binding
/ affects cotreatment
/ decreases reaction
/ increases chemical synthesis
protein 17389590
D001205 10797 MTHFD2
NMDMC
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (EC:3.5.4.9 1.5.1.15) Ascorbic Acid results in decreased expression of MTHFD2 mRNA decreases expression
mRNA 19197388
D001205 4605 MYBL2
B-MYB
BMYB
v-myb avian myeloblastosis viral oncogene homolog-like 2 [Quercetin co-treated with Ascorbic Acid] results in increased expression of MYBL2 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 4640 MYO1A
BBMI
DFNA48
MIHC
MYHL
myosin IA [Quercetin co-treated with Ascorbic Acid] results in decreased expression of MYO1A mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 4677 NARS
ASNRS
NARS1
asparaginyl-tRNA synthetase (EC:6.1.1.22) Ascorbic Acid results in decreased expression of NARS mRNA decreases expression
mRNA 19197388
D001205 10397 NDRG1
CAP43
CMT4D
DRG-1
DRG1
GC4
HMSNL
NDR1
NMSL
PROXY1
RIT42
RTP
TARG1
TDD5
N-myc downstream regulated 1 Ascorbic Acid inhibits the reaction [nickel sulfate results in increased expression of NDRG1 protein] decreases reaction
/ increases expression
protein 16288478
D001205 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 Ascorbic Acid inhibits the reaction [resveratrol results in increased activity of NFE2L2 promoter] decreases reaction
/ increases activity
promoter 21199573
D001205 4800 NFYA
CBF-A
CBF-B
HAP2
NF-YA
nuclear transcription factor Y, alpha [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NFYA mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 4814 NINJ1
NIN1
NINJURIN
ninjurin 1 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NINJ1 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 7080 NKX2-1
BCH
BHC
NK-2
NKX2.1
NKX2A
TEBP
TITF1
TTF-1
TTF1
NK2 homeobox 1 Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of NKX2-1 mRNA] decreases expression
/ decreases reaction
mRNA 15083329
D001205 7080 NKX2-1
BCH
BHC
NK-2
NKX2.1
NKX2A
TEBP
TITF1
TTF-1
TTF1
NK2 homeobox 1 Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of NKX2-1 protein] decreases expression
/ decreases reaction
protein 15083329
D001205 4830 NME1
AWD
GAAD
NB
NBS
NDKA
NDPK-A
NDPKA
NM23
NM23-H1
NME/NM23 nucleoside diphosphate kinase 1 (EC:2.7.4.6) [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of NME1 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 4843 NOS2
HEP-NOS
INOS
NOS
NOS2A
nitric oxide synthase 2, inducible (EC:1.14.13.39) Ascorbic Acid inhibits the reaction [Aspirin results in increased expression of NOS2 protein] decreases reaction
/ increases expression
protein 17218764
D001205 4843 NOS2
HEP-NOS
INOS
NOS
NOS2A
nitric oxide synthase 2, inducible (EC:1.14.13.39) Ascorbic Acid results in increased activity of NOS2 protein increases activity
protein 20179380
D001205 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) [Isosorbide Dinitrate co-treated with Ascorbic Acid] affects the expression of NOS3 mRNA affects cotreatment
/ affects expression
mRNA 15719745
D001205 2908 NR3C1
GCCR
GCR
GR
GRL
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of NR3C1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 8013 NR4A3
CHN
CSMF
MINOR
NOR1
TEC
nuclear receptor subfamily 4, group A, member 3 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of NR4A3 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 4973 OLR1
CLEC8A
LOX1
LOXIN
SCARE1
SLOX1
oxidized low density lipoprotein (lectin-like) receptor 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of OLR1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 10956 OS9
ERLEC2
OS-9
osteosarcoma amplified 9, endoplasmic reticulum lectin [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of OS9 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 8974 P4HA2
prolyl 4-hydroxylase, alpha polypeptide II (EC:1.14.11.2) Ascorbic Acid results in decreased expression of P4HA2 mRNA decreases expression
mRNA 19197388
D001205 54681 P4HTM
EGLN4
HIFPH4
P4H-TM
PH-4
PH4
PHD4
prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) [alpha-ketoglutaric acid co-treated with Ascorbic Acid co-treated with ferrous chloride] results in increased activity of P4HTM protein affects cotreatment
/ increases activity
protein 19263519
D001205 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Ascorbic Acid inhibits the reaction [Fenretinide results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 16407847
D001205 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Ascorbic Acid promotes the reaction [chromium hexavalent ion results in increased cleavage of PARP1 protein] increases cleavage
/ increases reaction
protein 17301063
D001205 5106 PCK2
PEPCK
PEPCK-M
PEPCK2
phosphoenolpyruvate carboxykinase 2 (mitochondrial) (EC:4.1.1.32) Ascorbic Acid results in decreased expression of PCK2 mRNA decreases expression
mRNA 19197388
D001205 64714 PDIA2
PDA2
PDI
PDIP
PDIR
protein disulfide isomerase family A, member 2 (EC:5.3.4.1) Ascorbic Acid results in decreased expression of PDIA2 mRNA decreases expression
mRNA 19197388
D001205 2923 PDIA3
ER60
ERp57
ERp60
ERp61
GRP57
GRP58
HsT17083
P58
PI-PLC
protein disulfide isomerase family A, member 3 (EC:5.3.4.1) Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of PDIA3 mRNA] decreases reaction
/ increases expression
mRNA 17353921
D001205 2923 PDIA3
ER60
ERp57
ERp60
ERp61
GRP57
GRP58
HsT17083
P58
PI-PLC
protein disulfide isomerase family A, member 3 (EC:5.3.4.1) Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of PDIA3 protein] decreases reaction
/ increases expression
protein 17353921
D001205 26227 PHGDH
3-PGDH
3PGDH
PDG
PGAD
PGD
PGDH
SERA
phosphoglycerate dehydrogenase (EC:1.1.1.95) Ascorbic Acid results in decreased expression of PHGDH mRNA decreases expression
mRNA 19197388
D001205 22822 PHLDA1
DT1P1B11
PHRIP
TDAG51
pleckstrin homology-like domain, family A, member 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of PHLDA1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 7262 PHLDA2
BRW1C
BWR1C
HLDA2
IPL
TSSC3
pleckstrin homology-like domain, family A, member 2 [Quercetin co-treated with Ascorbic Acid] results in increased expression of PHLDA2 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 11145 PLA2G16
AdPLA
H-REV107-1
HRASLS3
HREV107
HREV107-1
HREV107-3
HRSL3
phospholipase A2, group XVI (EC:3.1.1.4 3.1.1.32) [Quercetin co-treated with Ascorbic Acid] results in increased expression of PLA2G16 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 5340 PLG
plasminogen (EC:3.4.21.7) Ascorbic Acid inhibits the reaction [Arsenic promotes the reaction [Humic Substances results in decreased activity of PLG protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 11419606
D001205 5340 PLG
plasminogen (EC:3.4.21.7) Ascorbic Acid inhibits the reaction [Humic Substances results in decreased activity of PLG protein] decreases activity
/ decreases reaction
protein 11419606
D001205 5347 PLK1
PLK
STPK13
polo-like kinase 1 (EC:2.7.11.21) [Quercetin co-treated with Ascorbic Acid] results in increased expression of PLK1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 5366 PMAIP1
APR
NOXA
phorbol-12-myristate-13-acetate-induced protein 1 Ascorbic Acid inhibits the reaction [Fenretinide results in increased expression of PMAIP1 mRNA] decreases reaction
/ increases expression
mRNA 17216584
D001205 5376 PMP22
CMT1A
CMT1E
DSS
GAS-3
HMSNIA
HNPP
Sp110
peripheral myelin protein 22 Ascorbic Acid results in decreased expression of PMP22 mRNA decreases expression
mRNA 15034573
17303424
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) 1,2-dioleoyl-sn-glycero-3-phosphoglycerol inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein] affects cotreatment
/ decreases activity
/ decreases reaction
protein 12871208
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) 1,2-dioleoyl-sn-glycero-3-phosphoglycerol inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) 1,2-dipalmitoylphosphatidylglycerol inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) 1,2-oleoylphosphatidylcholine inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein] affects cotreatment
/ decreases activity
/ decreases reaction
protein 12871208
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with Copper Sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] affects cotreatment
/ decreases reaction
/ increases hydrolysis
protein 15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with Copper Sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] affects cotreatment
/ decreases reaction
/ increases hydrolysis
protein 15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein affects cotreatment
/ decreases activity
protein 12871208
15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon] affects cotreatment
/ decreases reaction
/ increases hydrolysis
protein 15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] affects cotreatment
/ decreases reaction
/ increases hydrolysis
protein 15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Ascorbic Acid co-treated with ferrous sulfate] results in decreased activity of PON1 protein affects cotreatment
/ decreases activity
protein 12871208
15375178
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Ascorbic Acid results in decreased activity of PON1 protein decreases activity
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 16052486
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) CAT protein inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein] decreases activity
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) erucic acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein] affects cotreatment
/ decreases activity
/ decreases reaction
protein 12871208
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Hypochlorous Acid promotes the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein affects cotreatment
/ decreases activity
protein 16052486
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein affects cotreatment
/ decreases expression
protein 16052486
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Oleic Acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein] affects cotreatment
/ decreases activity
/ decreases reaction
protein 12871208
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Oleic Acid inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) palmitoleic acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein] affects cotreatment
/ decreases activity
/ decreases reaction
protein 12871208
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) PON1 protein results in increased metabolism of [Acrolein binds to Ascorbic Acid] affects binding
/ increases metabolic processing
protein 20353174
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) [PON1 protein results in increased metabolism of [Acrolein binds to Ascorbic Acid]] which results in increased chemical synthesis of 5,6,7,8-tetrahydroxy-4-oxooctanal affects binding
/ increases chemical synthesis
/ increases metabolic processing
protein 20353174
D001205 5444 PON1
ESA
MVCD5
PON
paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) Sulfhydryl Compounds inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]] decreases activity
/ decreases reaction
/ increases reaction
protein 15104111
D001205 5445 PON2
paraoxonase 2 (EC:3.1.1.2 3.1.1.81) PON2 protein results in increased metabolism of [Acrolein binds to Ascorbic Acid] affects binding
/ increases metabolic processing
protein 20353174
D001205 5445 PON2
paraoxonase 2 (EC:3.1.1.2 3.1.1.81) [PON2 protein results in increased metabolism of [Acrolein binds to Ascorbic Acid]] which results in increased chemical synthesis of 5,6,7,8-tetrahydroxy-4-oxooctanal affects binding
/ increases chemical synthesis
/ increases metabolic processing
protein 20353174
D001205 5460 POU5F1
OCT3
OCT4
OTF-3
OTF3
OTF4
Oct-3
Oct-4
POU class 5 homeobox 1 Ascorbic Acid results in increased expression of POU5F1 mRNA increases expression
mRNA 21166886
D001205 10891 PPARGC1A
LEM6
PGC-1(alpha)
PGC-1v
PGC1
PGC1A
PPARGC1
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha Ascorbic Acid results in increased expression of PPARGC1A mRNA increases expression
mRNA 23056435
D001205 5588 PRKCQ
PRKCT
nPKC-theta
protein kinase C, theta (EC:2.7.11.13) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of PRKCQ mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 38175 Ascorbic Acid results in decreased expression of PSA mRNA decreases expression
mRNA 19197388
D001205 5702 PSMC3
TBP1
proteasome (prosome, macropain) 26S subunit, ATPase, 3 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of PSMC3 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Ascorbic Acid inhibits the reaction [Aspirin results in increased expression of PTGS2 mRNA] decreases reaction
/ increases expression
mRNA 17218764
D001205 5865 RAB3B
RAB3B, member RAS oncogene family [Quercetin co-treated with Ascorbic Acid] results in increased expression of RAB3B mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 5870 RAB6A
RAB6
RAB6A, member RAS oncogene family [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of RAB6A mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Ascorbic Acid promotes the reaction [arsenic trioxide results in increased activity of RAC1 protein] increases activity
/ increases reaction
protein 12239215
D001205 5889 RAD51C
BROVCA3
FANCO
R51H3
RAD51L2
RAD51 paralog C [Tretinoin co-treated with Ascorbic Acid] results in increased expression of RAD51C mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 25788 RAD54B
RDH54
RAD54 homolog B (S. cerevisiae) [Quercetin co-treated with Ascorbic Acid] results in increased expression of RAD54B mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 1827 RCAN1
ADAPT78
CSP1
DSC1
DSCR1
MCIP1
RCN1
regulator of calcineurin 1 [Tretinoin co-treated with Ascorbic Acid] results in increased expression of RCAN1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 860 RUNX2
AML3
CBF-alpha-1
CBFA1
CCD
CCD1
CLCD
OSF-2
OSF2
PEA2aA
PEBP2aA
runt-related transcription factor 2 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA affects cotreatment
/ increases expression
mRNA 17692823
D001205 795 S100G
CABP
CABP1
CABP9K
CALB3
S100 calcium binding protein G [Quercetin co-treated with Ascorbic Acid] results in decreased expression of S100G mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 5055 SERPINB2
HsT1201
PAI
PAI-2
PAI2
PLANH2
serpin peptidase inhibitor, clade B (ovalbumin), member 2 Ascorbic Acid results in decreased expression of SERPINB2 mRNA decreases expression
mRNA 19197388
D001205 83667 SESN2
HI95
SES2
SEST2
sestrin 2 [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA affects cotreatment
/ decreases expression
mRNA 20530418
D001205 83667 SESN2
HI95
SES2
SEST2
sestrin 2 nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 20530418
D001205 6439 SFTPB
PSP-B
SFTB3
SFTP3
SMDP1
SP-B
surfactant protein B Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of SFTPB mRNA] decreases expression
/ decreases reaction
mRNA 16490937
D001205 6439 SFTPB
PSP-B
SFTB3
SFTP3
SMDP1
SP-B
surfactant protein B Ascorbic Acid inhibits the reaction [nitrofen results in decreased expression of SFTPB protein] decreases expression
/ decreases reaction
protein 15083329
D001205 6472 SHMT2
GLYA
SHMT
serine hydroxymethyltransferase 2 (mitochondrial) (EC:2.1.2.1) Ascorbic Acid results in decreased expression of SHMT2 mRNA decreases expression
mRNA 19197388
D001205 6476 SI
sucrase-isomaltase (alpha-glucosidase) (EC:3.2.1.10 3.2.1.48) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of SI mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 4891 SLC11A2
DCT1
DMT1
NRAMP2
solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 Ascorbic Acid results in decreased expression of SLC11A2 protein decreases expression
protein 18815723
D001205 4891 SLC11A2
DCT1
DMT1
NRAMP2
solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 Ascorbic Acid results in increased expression of SLC11A2 protein increases expression
protein 18815723
D001205 10864 SLC22A7
NLT
OAT2
solute carrier family 22 (organic anion transporter), member 7 SLC22A7 protein results in increased transport of Ascorbic Acid increases transport
protein 15901346
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 Ascorbic Acid deficiency results in increased expression of SLC23A1 mRNA increases expression
mRNA 20471816
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 Ascorbic Acid deficiency results in increased expression of SLC23A1 protein increases expression
protein 20471816
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 Ascorbic Acid results in decreased expression of SLC23A1 mRNA decreases expression
mRNA 20471816
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 Ascorbic Acid results in decreased expression of SLC23A1 protein decreases expression
protein 20471816
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 Quercetin inhibits the reaction [SLC23A1 protein results in increased transport of Ascorbic Acid] decreases reaction
/ increases transport
protein 11834736
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 SLC23A1 gene polymorphism affects the abundance of Ascorbic Acid affects abundance
gene 20519558
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 SLC23A1 protein affects the transport of Ascorbic Acid affects transport
protein 12381735
D001205 9963 SLC23A1
SLC23A2
SVCT1
YSPL3
solute carrier family 23 (ascorbic acid transporter), member 1 SLC23A1 protein results in increased transport of Ascorbic Acid increases transport
protein 11834736
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Ascorbic Acid inhibits the reaction [nickel sulfate results in decreased expression of SLC23A2 mRNA] decreases expression
/ decreases reaction
mRNA 16288478
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Diclofenac inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Estradiol inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Genistein inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Hydrocortisone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Indomethacin inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Progesterone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 9962 SLC23A2
NBTL1
SLC23A1
SVCT2
YSPL2
solute carrier family 23 (ascorbic acid transporter), member 2 Quercetin inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid] decreases reaction
/ increases uptake
protein 17092984
D001205 79677 SMC6
SMC-6
SMC6L1
hSMC6
structural maintenance of chromosomes 6 Ascorbic Acid results in decreased expression of SMC6 mRNA decreases expression
mRNA 19197388
D001205 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) [Ascorbic Acid co-treated with Vitamin E] results in increased expression of SOD1 mRNA affects cotreatment
/ increases expression
mRNA 22207723
D001205 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) [Tretinoin co-treated with Ascorbic Acid] results in increased expression of SOD1 mRNA affects cotreatment
/ increases expression
mRNA 16443354
D001205 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Ascorbic Acid deficiency results in increased expression of SOD2 mRNA increases expression
mRNA 19932582
D001205 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Ascorbic Acid inhibits the reaction [HMOX1 protein results in increased expression of SOD2 mRNA] decreases reaction
/ increases expression
mRNA 10942521
D001205 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Ascorbic Acid results in increased expression of SOD2 mRNA increases expression
mRNA 19932582
D001205 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein results in increased susceptibility to Ascorbic Acid increases response to substance
protein 15130278
D001205 6657 SOX2
ANOP3
MCOPS3
SRY (sex determining region Y)-box 2 Ascorbic Acid results in increased expression of SOX2 mRNA increases expression
mRNA 21166886
D001205 6667 SP1
Sp1 transcription factor Ascorbic Acid results in decreased expression of SP1 protein decreases expression
protein 21919647
D001205 6670 SP3
SPR2
Sp3 transcription factor Ascorbic Acid results in decreased expression of SP3 protein decreases expression
protein 21919647
D001205 6671 SP4
HF1B
SPR-1
Sp4 transcription factor Ascorbic Acid results in decreased expression of SP4 protein decreases expression
protein 21919647
D001205 6678 SPARC
ON
secreted protein, acidic, cysteine-rich (osteonectin) [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein affects cotreatment
/ increases expression
protein 17692823
D001205 6696 SPP1
BNSP
BSPI
ETA-1
OPN
secreted phosphoprotein 1 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPP1 protein affects cotreatment
/ increases expression
protein 17692823
D001205 6772 STAT1
CANDF7
ISGF-3
STAT91
signal transducer and activator of transcription 1, 91kDa Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT1 protein]] decreases reaction
/ increases phosphorylation
protein 16896058
D001205 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) Ascorbic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF protein results in increased phosphorylation of STAT3 protein]] decreases reaction
/ increases phosphorylation
protein 16896058
D001205 9262 STK17B
DRAK2
serine/threonine kinase 17b (EC:2.7.11.1) [Quercetin co-treated with Ascorbic Acid] results in increased expression of STK17B mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 6817 SULT1A1
HAST1/HAST2
P-PST
PST
ST1A1
ST1A3
STP
STP1
TSPST1
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 (EC:2.8.2.1) Ascorbic Acid results in decreased expression of SULT1A1 mRNA decreases expression
mRNA 21144891
D001205 6818 SULT1A3
HAST
HAST3
M-PST
ST1A3/ST1A4
ST1A5
STM
TL-PST
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 (EC:2.8.2.1) Ascorbic Acid results in decreased expression of SULT1A3 mRNA decreases expression
mRNA 21144891
D001205 20888 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of SULT1C1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 6822 SULT2A1
DHEA-ST
DHEAS
HST
ST2
ST2A1
ST2A3
STD
hSTa
sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 (EC:2.8.2.14) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of SULT2A1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 6876 TAGLN
SM22
SMCC
TAGLN1
WS3-10
transgelin [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of TAGLN mRNA affects cotreatment
/ increases expression
mRNA 18607632
D001205 6876 TAGLN
SM22
SMCC
TAGLN1
WS3-10
transgelin Ascorbic Acid results in increased expression of TAGLN mRNA increases expression
mRNA 18607632
D001205 6897 TARS
ThrRS
threonyl-tRNA synthetase (EC:6.1.1.3) Ascorbic Acid results in decreased expression of TARS mRNA decreases expression
mRNA 19197388
D001205 6901 TAZ
BTHS
CMD3A
EFE
EFE2
G4.5
LVNCX
Taz1
tafazzin [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of TAZ mRNA affects cotreatment
/ increases expression
mRNA 17692823
D001205 7018 TF
PRO1557
PRO2086
TFQTL1
transferrin [Quercetin co-treated with Ascorbic Acid] results in decreased expression of TF mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7032 TFF2
SML1
SP
trefoil factor 2 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of TFF2 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 mRNA affects cotreatment
/ increases expression
protein 18607632
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of ACTA2 protein affects cotreatment
/ increases expression
protein 18607632
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 mRNA affects cotreatment
/ increases expression
protein 18607632
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of CNN1 protein affects cotreatment
/ increases expression
protein 18607632
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Ascorbic Acid co-treated with TGFB1 protein] results in increased expression of TAGLN mRNA affects cotreatment
/ increases expression
protein 18607632
D001205 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of TGFB1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 7076 TIMP1
CLGI
EPA
EPO
HCI
TIMP
TIMP metallopeptidase inhibitor 1 Ascorbic Acid results in increased expression of TIMP1 protein increases expression
protein 12510807
D001205 4071 TM4SF1
H-L6
L6
M3S1
TAAL6
transmembrane 4 L six family member 1 [Quercetin co-treated with Ascorbic Acid] results in increased expression of TM4SF1 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 164656 TMPRSS6
IRIDA
transmembrane protease, serine 6 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of TMPRSS6 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ascorbic Acid inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide] decreases reaction
/ increases abundance
protein 12723939
D001205 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ascorbic Acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide] decreases reaction
/ increases abundance
protein 12723939
D001205 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ascorbic Acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 12723939
D001205 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b Ascorbic Acid results in decreased expression of TNFRSF11B mRNA decreases expression
mRNA 17664058
D001205 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of TNFSF10 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 20530418
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein affects cotreatment
/ decreases expression
protein 20530418
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Ascorbic Acid inhibits the reaction [potassium bromate results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 20067818
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 mRNA] decreases reaction
/ increases expression
mRNA 22245848
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Ascorbic Acid inhibits the reaction [Silicon Dioxide results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 22245848
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Ascorbic Acid promotes the reaction [Cisplatin results in increased expression of TP53 protein] increases expression
/ increases reaction
protein 21429301
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 20530418
D001205 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 20530418
D001205 11257 TP53TG1
LINC00096
NCRNA00096
P53TG1
P53TG1-D
TP53AP1
TP53 target 1 (non-protein coding) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of TP53TG1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 57761 TRIB3
C20orf97
NIPK
SINK
SKIP3
TRB3
tribbles pseudokinase 3 Ascorbic Acid results in decreased expression of TRIB3 mRNA decreases expression
mRNA 19197388
D001205 57761 TRIB3
C20orf97
NIPK
SINK
SKIP3
TRB3
tribbles pseudokinase 3 [Quercetin co-treated with Ascorbic Acid] results in increased expression of TRIB3 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 9322 TRIP10
CIP4
HSTP
STOT
STP
thyroid hormone receptor interactor 10 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of TRIP10 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 7224 TRPC5
TRP5
transient receptor potential cation channel, subfamily C, member 5 Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]] decreases reaction
/ increases reaction
/ increases transport
protein 21127073
D001205 7224 TRPC5
TRP5
transient receptor potential cation channel, subfamily C, member 5 Ascorbic Acid inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]] decreases reaction
/ increases reaction
/ increases transport
protein 21127073
D001205 7224 TRPC5
TRP5
transient receptor potential cation channel, subfamily C, member 5 resveratrol promotes the reaction [Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]] decreases reaction
/ increases reaction
/ increases transport
protein 21127073
D001205 7299 TYR
ATN
CMM8
OCA1
OCA1A
OCAIA
SHEP3
tyrosinase (EC:1.14.18.1) ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid] decreases reaction
/ increases oxidation
protein 20685355
D001205 7299 TYR
ATN
CMM8
OCA1
OCA1A
OCAIA
SHEP3
tyrosinase (EC:1.14.18.1) Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid] decreases reaction
/ increases oxidation
protein 20685355
D001205 7299 TYR
ATN
CMM8
OCA1
OCA1A
OCAIA
SHEP3
tyrosinase (EC:1.14.18.1) [TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of Ascorbic Acid increases oxidation
protein 20685355
D001205 7319 UBE2A
HHR6A
MRXS30
MRXSN
RAD6A
UBC2
ubiquitin-conjugating enzyme E2A (EC:6.3.2.19) [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of UBE2A mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 54575 UGT1A10
UDPGT
UGT-1J
UGT1-10
UGT1.10
UGT1J
UDP glucuronosyltransferase 1 family, polypeptide A10 (EC:2.4.1.17) [Quercetin co-treated with Ascorbic Acid] results in increased expression of UGT1A10 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 54600 UGT1A9
HLUGP4
LUGP4
UDPGT
UDPGT_1-9
UGT-1I
UGT1-09
UGT1-9
UGT1.9
UGT1AI
UGT1I
UDP glucuronosyltransferase 1 family, polypeptide A9 (EC:2.4.1.17) [Quercetin co-treated with Ascorbic Acid] results in increased expression of UGT1A9 mRNA affects cotreatment
/ increases expression
mRNA 17639512
D001205 7366 UGT2B15
HLUG4
UDPGT_2B8
UDPGT2B15
UDPGTH3
UGT2B8
UDP glucuronosyltransferase 2 family, polypeptide B15 (EC:2.4.1.17) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of UGT2B15 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of VCAM1 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 7428 VHL
HRCA1
RCA1
VHL1
pVHL
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with alpha-ketoglutaric acid co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein] affects binding
/ affects cotreatment
/ increases reaction
protein 19263519
D001205 7428 VHL
HRCA1
RCA1
VHL1
pVHL
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase manganese chloride inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with alpha-ketoglutaric acid co-treated with Ascorbic Acid co-treated with ferrous chloride] promotes the reaction [VHL protein binds to HIF1A protein]] affects binding
/ affects cotreatment
/ decreases reaction
/ increases reaction
protein 19263519
D001205 55350 VNN3
HSA238982
vanin 3 Ascorbic Acid affects the expression of VNN3 mRNA affects expression
mRNA 19932582
D001205 55350 VNN3
HSA238982
vanin 3 Ascorbic Acid deficiency results in increased expression of VNN3 mRNA increases expression
mRNA 19932582
D001205 7443 VRK1
PCH1
PCH1A
vaccinia related kinase 1 (EC:2.7.11.1) [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of VRK1 mRNA affects cotreatment
/ decreases expression
mRNA 16443354
D001205 7453 WARS
GAMMA-2
IFI53
IFP53
tryptophanyl-tRNA synthetase (EC:6.1.1.2) Ascorbic Acid results in decreased expression of WARS mRNA decreases expression
mRNA 19197388
D001205 10352 WARS2
TrpRS
tryptophanyl tRNA synthetase 2, mitochondrial (EC:6.1.1.2) Ascorbic Acid results in decreased expression of WARS2 mRNA decreases expression
mRNA 19197388
D001205 25937 WWTR1
TAZ
WW domain containing transcription regulator 1 [Quercetin co-treated with Ascorbic Acid] results in decreased expression of WWTR1 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7512 XPNPEP2
APP2
X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound (EC:3.4.11.9) [Quercetin co-treated with Ascorbic Acid] results in decreased expression of XPNPEP2 mRNA affects cotreatment
/ decreases expression
mRNA 17639512
D001205 7515 XRCC1
RCC
X-ray repair complementing defective repair in Chinese hamster cells 1 Ascorbic Acid inhibits the reaction [Fenretinide results in decreased expression of XRCC1 protein] decreases expression
/ decreases reaction
protein 16124896
D001205 7515 XRCC1
RCC
X-ray repair complementing defective repair in Chinese hamster cells 1 Ascorbic Acid inhibits the reaction [Reactive Oxygen Species results in decreased expression of XRCC1 protein] decreases expression
/ decreases reaction
protein 16124896
D001205 7515 XRCC1
RCC
X-ray repair complementing defective repair in Chinese hamster cells 1 Ascorbic Acid inhibits the reaction [XRCC1 mutant form results in increased susceptibility to chromium hexavalent ion] decreases reaction
/ increases response to substance
mutant form 22241526
D001205 7718 ZNF165
CT53
LD65
ZSCAN7
zinc finger protein 165 [Quercetin co-treated with Ascorbic Acid] results in increased expression of ZNF165 mRNA affects cotreatment
/ increases expression
mRNA 17639512

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (58)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#103470 Albinism, ocular, with sensorineural deafness P14679
#203100 Albinism, oculocutaneous, type ia; oca1a P14679
#606952 Albinism, oculocutaneous, type ib; oca1b P14679
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#609820 Erythrocytosis, familial, 3; ecyt3 Q9GZT9
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 P04626
#610140 Heart-hand syndrome, slovenian type P02545
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#603932 Intervertebral disc disease; idd P14780
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
#608516 Major depressive disorder; mdd P08172
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#601800 Skin/hair/eye pigmentation, variation in, 3; shep3 P14679
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#190300 Tremor, hereditary essential, 1; etm1 P35462
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (50)

KEGG disease name UniProt
H00016 Oral cancer P00533 (related)
P00533 (marker)
H00017 Esophageal cancer P00533 (related)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
H00027 Ovarian cancer P04626 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P35354 (related)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00036 Osteosarcoma P08684 (marker)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00168 Oculocutaneous albinism (OCA) P14679 (related)
H00038 Malignant melanoma P14679 (marker)
H00025 Penile cancer P14780 (related)
P35354 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00236 Congenital polycythemia Q9GZT9 (related)

Diseases related to CTD interactions

98 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 D001205 Acute Kidney Injury marker/mechanism
18714631
D055371 D001205 Acute Lung Injury therapeutic
15612528
D000647 D001205 Amnesia therapeutic
7582819
D000740 D001205 Anemia marker/mechanism
17497326
D018798 D001205 Anemia, Iron-Deficiency therapeutic
22169218
D000749 D001205 Anemia, Megaloblastic therapeutic
16353713
D000756 D001205 Anemia, Sideroblastic therapeutic
673833
D001206 D001205 Ascorbic Acid Deficiency therapeutic
19710200
D001424 D001205 Bacterial Infections therapeutic
12669766
D001766 D001205 Blindness therapeutic
1341094
D001847 D001205 Bone Diseases marker/mechanism
21281732
D001927 D001205 Brain Diseases therapeutic
20305954
D002545 D001205 Brain Ischemia therapeutic
18044087
D001943 D001205 Breast Neoplasms therapeutic
16443354
D002277 D001205 Carcinoma therapeutic
16345077
D006528 D001205 Carcinoma, Hepatocellular marker/mechanism
therapeutic
7728963
19229483
D009202 D001205 Cardiomyopathies therapeutic
1962586
10533957
D018376 D001205 Cardiovascular Abnormalities therapeutic
20068362
D002318 D001205 Cardiovascular Diseases marker/mechanism
15531665
19769483
D002375 D001205 Catalepsy marker/mechanism
therapeutic
3088632
3703914
D002386 D001205 Cataract therapeutic
8698541
D002471 D001205 Cell Transformation, Neoplastic therapeutic
21344382
D002607 D001205 Charcot-Marie-Tooth Disease therapeutic
15034573
D002869 D001205 Chromosome Aberrations therapeutic
7678149
D003139 D001205 Common Cold therapeutic
17323712
D020918 D001205 Complex Regional Pain Syndromes therapeutic
20224742
D003327 D001205 Coronary Disease therapeutic
8698541
D003681 D001205 Dehydration marker/mechanism
17497326
D003924 D001205 Diabetes Mellitus, Type 2 marker/mechanism
16506275
D003928 D001205 Diabetic Nephropathies therapeutic
18763636
D003930 D001205 Diabetic Retinopathy therapeutic
18779489
D056486 D001205 Drug-Induced Liver Injury therapeutic
21791388
D062787 D001205 Drug Overdose marker/mechanism
18714631
D064420 D001205 Drug-Related Side Effects and Adverse Reactions therapeutic
8746330
C538011 D001205 Eales disease marker/mechanism
9068938
D004890 D001205 Erythema therapeutic
19800932
D005221 D001205 Fatigue marker/mechanism
17497326
D006029 D001205 Glycosuria therapeutic
7909430
D006130 D001205 Growth Disorders therapeutic
20068362
D006212 D001205 Hallucinations marker/mechanism
8767052
D006330 D001205 Heart Defects, Congenital therapeutic
16080930
D006548 D001205 Hernia, Diaphragmatic therapeutic
16490937
16863852
D015658 D001205 HIV Infections therapeutic
9764785
D006959 D001205 Hyperoxaluria marker/mechanism
54676
54776
18042297
D006965 D001205 Hyperplasia marker/mechanism
6681793
D006973 D001205 Hypertension marker/mechanism
therapeutic
9880127
10904027
11729227
14520025
15190049
20360751
D006977 D001205 Hypertension, Renal therapeutic
20053703
D007022 D001205 Hypotension therapeutic
3706053
15612528
D007037 D001205 Hypothyroidism therapeutic
12587721
146850 D001205 IMMUNE SUPPRESSION therapeutic
15020195
D007674 D001205 Kidney Diseases therapeutic
7909430
17448119
18414974
18536492
D007683 D001205 Kidney Tubular Necrosis, Acute marker/mechanism
therapeutic
1678558
7902115
D007859 D001205 Learning Disorders marker/mechanism
19703495
D007945 D001205 Leukemia, Lymphoid therapeutic
12750841
D008103 D001205 Liver Cirrhosis therapeutic
22149461
D008114 D001205 Liver Neoplasms, Experimental marker/mechanism
18544905
D008171 D001205 Lung Diseases therapeutic
16863852
D008175 D001205 Lung Neoplasms therapeutic
16401635
D020149 D001205 Manganese Poisoning therapeutic
21940818
D008630 D001205 Mercury Poisoning therapeutic
18536492
D048629 D001205 Micronuclei, Chromosome-Defective marker/mechanism
therapeutic
7992229
17169990
D009120 D001205 Muscle Cramp therapeutic
11427639
D009135 D001205 Muscular Diseases therapeutic
5111643
D009203 D001205 Myocardial Infarction therapeutic
16444596
16635105
19466570
19494560
D009325 D001205 Nausea marker/mechanism
17497326
D009336 D001205 Necrosis marker/mechanism
therapeutic
10533957
15223132
15577407
19482829
21645609
D009369 D001205 Neoplasms therapeutic
8698541
20433922
D009374 D001205 Neoplasms, Experimental therapeutic
19197388
19224539
19671184
21878346
22139585
D009395 D001205 Nephritis, Interstitial marker/mechanism
18042297
D053040 D001205 Nephrolithiasis marker/mechanism
18042297
18714631
D009410 D001205 Nerve Degeneration therapeutic
17959157
D009422 D001205 Nervous System Diseases therapeutic
2554183
D009765 D001205 Obesity therapeutic
17217161
D009845 D001205 Oligospermia therapeutic
8671712
19429265
20305954
D010149 D001205 Pain, Postoperative therapeutic
5111643
D010212 D001205 Papilloma marker/mechanism
1752781
6500233
D016491 D001205 Peripheral Vascular Diseases therapeutic
20174656
D011041 D001205 Poisoning therapeutic
22245848
D011230 D001205 Precancerous Conditions marker/mechanism
1752781
D011471 D001205 Prostatic Neoplasms therapeutic
16345077
D011507 D001205 Proteinuria therapeutic
7919151
20360751
D011561 D001205 Pseudoxanthoma Elasticum therapeutic
17845175
D011605 D001205 Psychoses, Substance-Induced marker/mechanism
8767052
D011654 D001205 Pulmonary Edema therapeutic
15612528
D011657 D001205 Pulmonary Eosinophilia therapeutic
14606601
D011658 D001205 Pulmonary Fibrosis therapeutic
18759078
D051437 D001205 Renal Insufficiency marker/mechanism
18042297
D012174 D001205 Retinitis Pigmentosa therapeutic
16849425
D012614 D001205 Scurvy therapeutic
4538611
8698541
D012640 D001205 Seizures therapeutic
17543232
18096215
20602035
20716907
20801149
D012871 D001205 Skin Diseases therapeutic
18709164
D013226 D001205 Status Epilepticus therapeutic
17512118
18096215
D013274 D001205 Stomach Neoplasms marker/mechanism
6680729
D013276 D001205 Stomach Ulcer therapeutic
17218764
18726076
D020521 D001205 Stroke therapeutic
16403987
16517955
D013375 D001205 Substance Withdrawal Syndrome therapeutic
19418264
D013921 D001205 Thrombocytopenia marker/mechanism
17497326
D001749 D001205 Urinary Bladder Neoplasms marker/mechanism
therapeutic
1752781
2004360
6500233
6536604
6680729
16345077